|
1
|
Deininger MW, Goldman JM and Melo JV: The
molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356.
2000.
|
|
2
|
Hehlmann R, Saussele S, Voskanyan A and
Silver RT: Management of CML-blast crisis. Best Pract Res Clin
Haematol. 29:295–307. 2016.
|
|
3
|
Westermarck J: Targeted therapies don’t
work for a reason; the neglected tumor suppressor phosphatase PP2A
strikes back. FEBS J. 285:4139–4145. 2018.
|
|
4
|
Neviani P, Santhanam R, Trotta R, Notari
M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al:
The tumor suppressor PP2A is functionally inactivated in blast
crisis CML through the inhibitory activity of the BCR/ABL-regulated
SET protein. Cancer Cell. 8:355–368. 2005.
|
|
5
|
Schönthal AH: Role of serine/threonine
protein phosphatase 2A in cancer. Cancer Lett. 170:1–13. 2001.
|
|
6
|
Chang CC, Campoli M and Ferrone S: HLA
class I antigen expression in malignant cells: Why does it not
always correlate with CTL-mediated lysis? Curr Opin Immunol.
16:644–650. 2004.
|
|
7
|
Matsumoto S, Abe Y, Fujibuchi T, Takeuchi
T, Kito K, Ueda N, Shigemoto K and Gyo K: Characterization of a
MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun.
325:997–1004. 2004.
|
|
8
|
Gaudet S, Branton D and Lue RA:
Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl
Acad Sci USA. 97:5167–5172. 2000.
|
|
9
|
Nandi A, Tidwell M, Karp J and Rapoport
AP: Protein expression of PDZ-binding kinase is up-regulated in
hematologic malignancies and strongly down-regulated during
terminal differentiation of HL-60 leukemic cells. Blood Cells Mol
Dis. 32:240–245. 2004.
|
|
10
|
Wei DC, Yeh YC, Hung JJ, Chou TY, Wu YC,
Lu PJ, Cheng HC, Hsu YL, Kuo YL, Chen KY, et al: Overexpression of
T-LAK cell-originated protein kinase predicts poor prognosis in
patients with stage I lung adenocarcinoma. Cancer Sci. 103:731–738.
2012.
|
|
11
|
Ohashi T, Komatsu S, Ichikawa D, Miyamae
M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi
H, et al: Overexpression of PBK/TOPK contributes to tumor
development and poor outcome of esophageal squamous cell carcinoma.
Anticancer Res. 36:6457–6466. 2016.
|
|
12
|
Ohashi T, Komatsu S, Ichikawa D, Miyamae
M, Okajima W, Imamura T, Kiuchi J, Kosuga T, Konishi H, Shiozaki A,
et al: Overexpression of PBK/TOPK relates to tumour malignant
potential and poor outcome of gastric carcinoma. Br J Cancer.
116:218–226. 2017.
|
|
13
|
Chang CF, Chen SL, Sung WW, Hsieh MJ, Hsu
HT, Chen LH, Chen MK, Ko JL, Chen CJ and Chou MC: PBK/TOPK
expression predicts prognosis in oral cancer. Int J Mol Sci.
17:172016.
|
|
14
|
Park JH, Lin ML, Nishidate T, Nakamura Y
and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein
kinase, a putative cancer/testis antigen with an oncogenic activity
in breast cancer. Cancer Res. 66:9186–9195. 2006.
|
|
15
|
Abe Y, Takeuchi T, Kagawa-Miki L, Ueda N,
Shigemoto K, Yasukawa M and Kito K: A mitotic kinase TOPK enhances
Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes
cytokinesis. J Mol Biol. 370:231–245. 2007.
|
|
16
|
Park JH, Nishidate T, Nakamura Y and
Katagiri T: Critical roles of T-LAK cell-originated protein kinase
in cytokinesis. Cancer Sci. 101:403–411. 2010.
|
|
17
|
Seeling JM, Miller JR, Gil R, Moon RT,
White R and Virshup DM: Regulation of beta-catenin signaling by the
B56 subunit of protein phosphatase 2A. Science. 283:2089–2091.
1999.
|
|
18
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013.
|
|
19
|
Miki T, Kawamata N, Arai A, Ohashi K,
Nakamura Y, Kato A, Hirosawa S and Aoki N: Molecular cloning of the
breakpoint for 3q27 translocation in B-cell lymphomas and
leukemias. Blood. 83:217–222. 1994.
|
|
20
|
Tohda S, Nara N, Murohashi I and Aoki N:
Establishment of an interleukin-3-dependent leukemic cell line from
a patient with chronic lymphocytic leukemia in the acute phase.
Blood. 78:1789–1794. 1991.
|
|
21
|
Tohda S, Sakashita C, Fukuda T, Murakami N
and Nara N: Establishment of a double Philadelphia
chromosome-positive acute lymphoblastic leukemia-derived cell line,
TMD5: Effects of cytokines and differentiation inducers on growth
of the cells. Leuk Res. 23:255–261. 1999.
|
|
22
|
Sugamura K, Fujii M, Kannagi M, Sakitani
M, Takeuchi M and Hinuma Y: Cell surface phenotypes and expression
of viral antigens of various human cell lines carrying human T-cell
leukemia virus. Int J Cancer. 34:221–228. 1984.
|
|
23
|
Murakami Y, Hasegawa A, Ando S, Tanaka R,
Masuda T, Tanaka Y and Kannagi M: A novel mother-to-child human
T-cell leukaemia virus type-1 (HTLV-1) transmission model for
investigating the role of maternal anti-HTLV-1 antibodies using
orally infected mother rats. J Gen Virol. 98:835–846. 2017.
|
|
24
|
Klucher KM, Lopez DV and Daley GQ:
Secondary mutation maintains the transformed state in BaF3 cells
with inducible BCR/ABL expression. Blood. 91:3927–3934. 1998.
|
|
25
|
Kurosu T, Tsuji K, Kida A, Koyama T,
Yamamoto M and Miura O: Rottlerin synergistically enhances
imatinib-induced apoptosis of BCR/ABL-expressing cells through its
mitochondrial uncoupling effect independent of protein kinase
C-delta. Oncogene. 26:2975–2987. 2007.
|
|
26
|
Kurosu T, Ohki M, Wu N, Kagechika H and
Miura O: Sorafenib induces apoptosis specifically in cells
expressing BCR/ABL by inhibiting its kinase activity to activate
the intrinsic mitochondrial pathway. Cancer Res. 69:3927–3936.
2009.
|
|
27
|
Morita S, Kojima T and Kitamura T: Plat-E:
An efficient and stable system for transient packaging of
retroviruses. Gene Ther. 7:1063–1066. 2000.
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
29
|
Bassani-Sternberg M, Pletscher-Frankild S,
Jensen LJ and Mann M: Mass spectrometry of human leukocyte antigen
class I peptidomes reveals strong effects of protein abundance and
turnover on antigen presentation. Mol Cell Proteomics. 14:658–673.
2015.
|
|
30
|
Hofmann S, Glückmann M, Kausche S, Schmidt
A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M and Herr
W: Rapid and sensitive identification of major histocompatibility
complex class I-associated tumor peptides by Nano-LC MALDI MS/MS.
Mol Cell Proteomics. 4:1888–1897. 2005.
|
|
31
|
Hunt DF, Henderson RA, Shabanowitz J,
Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E and Engelhard
VH: Characterization of peptides bound to the class I MHC molecule
HLA-A2.1 by mass spectrometry. Science. 255:1261–1263. 1992.
|
|
32
|
Purcell AW and Gorman JJ:
Immunoproteomics: Mass spectrometry-based methods to study the
targets of the immune response. Mol Cell Proteomics. 3:193–208.
2004.
|
|
33
|
Zhang J, Xin L, Shan B, Chen W, Xie M,
Yuen D, Zhang W, Zhang Z, Lajoie GA and Ma B: PEAKS DB: de novo
sequencing assisted database search for sensitive and accurate
peptide identification. Mol Cell Proteomics.
11:M111.0105872012.
|
|
34
|
Liu J, Wu P, Gao F, Qi J, Kawana-Tachikawa
A, Xie J, Vavricka CJ, Iwamoto A, Li T and Gao GF: Novel
immunodominant peptide presentation strategy: A featured
HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by
intrachain hydrogen bonds from severe acute respiratory syndrome
coronavirus nucleocapsid protein. J Virol. 84:11849–11857.
2010.
|
|
35
|
Khodadoust MS, Olsson N, Wagar LE, Haabeth
OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, et
al: Antigen presentation profiling reveals recognition of lymphoma
immunoglobulin neoantigens. Nature. 543:723–727. 2017.
|
|
36
|
Dougherty JD, Garcia AD, Nakano I,
Livingstone M, Norris B, Polakiewicz R, Wexler EM, Sofroniew MV,
Kornblum HI and Geschwind DH: PBK/TOPK, a proliferating neural
progenitor-specific mitogen-activated protein kinase kinase. J
Neurosci. 25:10773–10785. 2005.
|
|
37
|
Head J, Lee LL, Field DJ and Lee JC:
Equilibrium and rapid kinetic studies on nocodazole-tubulin
interaction. J Biol Chem. 260:11060–11066. 1985.
|
|
38
|
Matsuo Y, Park JH, Miyamoto T, Yamamoto S,
Hisada S, Alachkar H and Nakamura Y: TOPK inhibitor induces
complete tumor regression in xenograft models of human cancer
through inhibition of cytokinesis. Sci Transl Med.
6:259ra1452014.
|
|
39
|
Yang YF, Pan YH, Cao Y, Fu J, Yang X,
Zhang MF and Tian QH: PDZ binding kinase, regulated by FoxM1,
enhances malignant phenotype via activation of β-Catenin signaling
in hepatocellular carcinoma. Oncotarget. 8:47195–47205. 2017.
|
|
40
|
Mancini M, Castagnetti F, Soverini S, Leo
E, De Benedittis C, Gugliotta G, Rosti G, Bavaro L, De Santis S,
Monaldi C, et al: FOXM1 transcription factor: A new component of
chronic myeloid leukemia stem cell proliferation advantage. J Cell
Biochem. 118:3968–3975. 2017.
|
|
41
|
Mumby M: The 3D structure of protein
phosphatase 2A: New insights into a ubiquitous regulator of cell
signaling. ACS Chem Biol. 2:99–103. 2007.
|
|
42
|
Eichhorn PJ, Creyghton MP and Bernards R:
Protein phosphatase 2A regulatory subunits and cancer. Biochim
Biophys Acta. 1795:1–15. 2009.
|
|
43
|
Rodgers JT, Vogel RO and Puigserver P:
Clk2 and B56β mediate insulin-regulated assembly of the PP2A
phosphatase holoenzyme complex on Akt. Mol Cell. 41:471–479.
2011.
|
|
44
|
Testa JR and Tsichlis PN: AKT signaling in
normal and malignant cells. Oncogene. 24:7391–7393. 2005.
|
|
45
|
Redaelli S, Piazza R, Rostagno R,
Magistroni V, Perini P, Marega M, Gambacorti-Passerini C and
Boschelli F: Activity of bosutinib, dasatinib, and nilotinib
against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol.
27:469–471. 2009.
|
